Rapamycin transiently induces mitochondrial remodeling to reprogram energy metabolism in old hearts

Aging

Volumn 8, Issue 2, 2016, Pages 314-327

  Chiao, Ying Ann ^a   Kolwicz, Stephen C ^a   Basisty, Nathan ^a   Gagnidze, Arni ^a   Zhang, Julia ^a   Gu, Haiwei ^a   Djukovic, Danijel ^a   Beyer, Richard P ^a   Raftery, Daniel ^a   MacCoss, Michael ^a   Tian, Rong ^a   Rabinovitch, Peter S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Autophagy; Cardiac aging; Mitochondrial metabolism; Rapamycin; Substrate utilization

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

AGING; ANIMAL; AUTOPHAGY; C57BL MOUSE; CARDIAC MUSCLE; DRUG EFFECTS; ENERGY METABOLISM; FEMALE; HEART; IMMUNOBLOTTING; MASS SPECTROMETRY; METABOLISM; MITOCHONDRION; MOUSE; NUCLEAR MAGNETIC RESONANCE; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

AGING; ANIMALS; AUTOPHAGY; ENERGY METABOLISM; FEMALE; HEART; IMMUNOBLOTTING; IMMUNOSUPPRESSIVE AGENTS; MASS SPECTROMETRY; MICE; MICE, INBRED C57BL; MITOCHONDRIA; MYOCARDIUM; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; REAL-TIME POLYMERASE CHAIN REACTION; SIROLIMUS;

EID: 84961203595     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100881     Document Type: Article

References (41)

1. Lakatta EG and Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. Circulation. 2003; 107:346-354.
2. Chiao YA and Rabinovitch PS. The Aging Heart. Cold Spring Harb Perspect Med. 2015; 5:a025148.
3. Dai DF, Santana LF, Vermulst M, Tomazela DM, Emond MJ, MacCoss MJ, Gollahon K, Martin GM, Loeb LA, Ladiges WC and Rabinovitch PS. Overexpression of catalase targeted to mitochondria attenuates murine cardiac aging. Circulation. 2009; 119:2789-2797.
4. Taffet GE, Pham TT and Hartley CJ. The age-associated alterations in late diastolic function in mice are improved by caloric restriction. The journals of gerontology Series A, Biological sciences and medical sciences. 1997; 52:B285-290.
5. Blagosklonny MV. Calorie restriction: decelerating mTORdriven aging from cells to organisms (including humans). Cell Cycle. 2010; 9:683-688.
6. Dai DF, Karunadharma PP, Chiao YA, Basisty N, Crispin D, Hsieh EJ, Chen T, Gu H, Djukovic D, Raftery D, Beyer RP, MacCoss MJ and Rabinovitch PS. Altered proteome turnover and remodeling by short-term caloric restriction or rapamycin rejuvenate the aging heart. Aging cell. 2014; 13:529-539.
7. Flynn JM, O'Leary MN, Zambataro CA, Academia EC, Presley MP, Garrett BJ, Zykovich A, Mooney SD, Strong R, Rosen CJ, Kapahi P, Nelson MD, Kennedy BK, et al. Late-life rapamycin treatment reverses age-related heart dysfunction. Aging cell. 2013; 12:851-862.
8. Kang SA, Pacold ME, Cervantes CL, Lim D, Lou HJ, Ottina K, Gray NS, Turk BE, Yaffe MB and Sabatini DM. mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science. 2013; 341:1236566.
9. Doenst T, Nguyen TD and Abel ED. Cardiac metabolism in heart failure: implications beyond ATP production. Circ Res. 2013; 113:709-724.
10. Stanley WC, Recchia FA and Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005; 85:1093-1129.
11. Dutta D, Calvani R, Bernabei R, Leeuwenburgh C and Marzetti E. Contribution of Impaired Mitochondrial Autophagy to Cardiac Aging Mechanisms and Therapeutic Opportunities. Circ Res. 2012; 110:1125-1138.
12. Sadoshima J and Izumo S. Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro. Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. Circ Res. 1995; 77:1040-1052.
13. Shioi T, McMullen JR, Tarnavski O, Converso K, Sherwood MC, Manning WJ and Izumo S. Rapamycin attenuates loadinduced cardiac hypertrophy in mice. Circulation. 2003; 107:1664-1670.
14. McMullen JR, Sherwood MC, Tarnavski O, Zhang L, Dorfman AL, Shioi T and Izumo S. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation. 2004; 109:3050-3055.
15. Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, Davis JG, Salmon AB, Richardson A, Ahima RS, Guertin DA, Sabatini DM and Baur JA. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science. 2012; 335:1638-1643.
16. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL and Sabatini DM. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006; 22:159-168.
17. Jung CH, Jun CB, Ro SH, Kim YM, Otto NM, Cao J, Kundu M and Kim DH. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol Biol Cell. 2009; 20:1992-2003.
18. Kim J, Kundu M, Viollet B and Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011; 13:132-141.
19. Haspel J, Shaik RS, Ifedigbo E, Nakahira K, Dolinay T, Englert JA and Choi AM. Characterization of macroautophagic flux in vivo using a leupeptin-based assay. Autophagy. 2011; 7:629-642.
20. Mihaylova MM and Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol. 2011; 13:1016-1023.
21. Habib SL, Kasinath BS, Arya RR, Vexler S and Velagapudi C. Novel mechanism of reducing tumourigenesis: upregulation of the DNA repair enzyme OGG1 by rapamycin-mediated AMPK activation and mTOR inhibition. Eur J Cancer. 2010; 46:2806-2820.
22. Mora A, Sakamoto K, McManus EJ and Alessi DR. Role of the PDK1-PKB-GSK3 pathway in regulating glycogen synthase and glucose uptake in the heart. FEBS Lett. 2005; 579:3632-3638.
23. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS and Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010; 90:207-258.
24. van Bilsen M, Smeets PJ, Gilde AJ and van der Vusse GJ. Metabolic remodelling of the failing heart: the cardiac burn-out syndrome? Cardiovasc Res. 2004; 61:218-226.
25. Sample J, Cleland JG and Seymour AM. Metabolic remodeling in the aging heart. J Mol Cell Cardiol. 2006; 40:56-63.
26. Kates AM, Herrero P, Dence C, Soto P, Srinivasan M, Delano DG, Ehsani A and Gropler RJ. Impact of aging on substrate metabolism by the human heart. J Am Coll Cardiol. 2003; 41:293-299.
27. Buller CL, Loberg RD, Fan MH, Zhu Q, Park JL, Vesely E, Inoki K, Guan KL and Brosius FC, 3rd. A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression. Am J Physiol Cell Physiol. 2008; 295:C836-843.
28. Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S, Vander Heiden MG, MacKeigan JP, Finan PM, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell. 2010; 39:171-183.
29. Sipula IJ, Brown NF and Perdomo G. Rapamycin-mediated inhibition of mammalian target of rapamycin in skeletal muscle cells reduces glucose utilization and increases fatty acid oxidation. Metabolism. 2006; 55:1637-1644.
30. Austin SL, Proia AD, Spencer-Manzon MJ, Butany J, Wechsler SB and Kishnani PS. Cardiac Pathology in Glycogen Storage Disease Type III. JIMD Rep. 2012; 6:65-72.
31. Gollob MH. Glycogen storage disease as a unifying mechanism of disease in the PRKAG2 cardiac syndrome. Biochem Soc Trans. 2003; 31:228-231.
32. Seifert BL, Snyder MS, Klein AA, O'Loughlin JE, Magid MS and Engle MA. Development of obstruction to ventricular outflow and impairment of inflow in glycogen storage disease of the heart: serial echocardiographic studies from birth to death at 6 months. Am Heart J. 1992; 123:239-242.
33. Yi H, Brooks ED, Thurberg BL, Fyfe JC, Kishnani PS and Sun B. Correction of glycogen storage disease type III with rapamycin in a canine model. J Mol Med (Berl). 2014; 92:641-650.
34. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM and Gray NS. An ATPcompetitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem. 2009; 284:8023-8032.
35. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009; 460:392-395.
36. Hsieh EJ, Shulman NJ, Dai DF, Vincow ES, Karunadharma PP, Pallanck L, Rabinovitch PS and MacCoss MJ. Topograph, a software platform for precursor enrichment corrected global protein turnover measurements. Mol Cell Proteomics. 2012; 111468-1474.
37. Kolwicz SC, Jr. and Tian R. Assessment of cardiac function and energetics in isolated mouse hearts using 31P NMR spectroscopy. J Vis Exp. 2010; 42.
38. Luptak I, Shen M, He H, Hirshman MF, Musi N, Goodyear LJ, Yan J, Wakimoto H, Morita H, Arad M, Seidman CE, Seidman JG, Ingwall JS, et al. Aberrant activation of AMP-activated protein kinase remodels metabolic network in favor of cardiac glycogen storage. J Clin Invest. 2007; 117:1432-1439.
39. Huber W, Carey VJ, Gentleman R, Anders S, Carlson M, Carvalho BS, Bravo HC, Davis S, Gatto L, Girke T, Gottardo R, Hahne F, Hansen KD, et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat Methods. 2015; 12:115-121.
40. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004; 3:Article3.
41. Xia J, Sinelnikov IV, Han B and Wishart DS. MetaboAnalyst 3.0-making metabolomics more meaningful. Nucleic Acids Res. 2015; 43:W251-257.